Pediatrix Medical Group (MD) Q3 2026 earnings review
Pediatrix patient volumes stabilize, but pricing gains nearly vanish
Pediatrix Medical Group, the hospital newborn and maternal physician group, saw patient visits stabilize just as its pricing boost vanished. Revenue at clinics owned a year ago rose 0.6%, because pricing gains slowed to 0.3% once last year's billing collection improvements entered the comparison base. Chief Executive Officer Mark S. Ordan said volume and pricing beat internal expectations, and the company lifted the middle of its full-year Adjusted EBITDA plan by $5 million, leaving 14% fourth-quarter growth by our math.
| Sales at clinics owned a year ago | +0.6% +1.9% in the second quarter |
|---|---|
| Revenue | $501.4M +1.7% from a year ago |
| Profit per share, excluding one-offs | $0.72 +7.5% from a year ago |
| Full-year Adjusted EBITDA outlook | Raised $5M middle of the range: $295M (+7%) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because stabilizing patient volumes and a higher full-year plan were offset by a sharp slowdown in pricing. For four quarters, better cash collections hid falling hospital baby-care volumes; this quarter, volumes grew 0.3%, but pricing barely moved and doctor pay rose faster than sales at existing clinics. Beating the profit range implied by the prior plan shows that the old forecast was cautious, while a third increase to excluded restructuring costs shows billing transition expenses are still not gone.
The question now is whether existing clinics can grow revenue fast enough to cover rising doctor salaries without the one-time collection boost. Bulls see stabilizing NICU days and rising commercial insurance mix carrying 2027, while bears see sub-1% pricing and per-share earnings propped up by buybacks. Fourth-quarter underlying pricing and the initial 2027 outlook will settle it.
🐂 Bull Case
Patient Volumes Stopped Falling After Three Negative Quarters
Pediatrix staffs hospital neonatal intensive care units (NICUs) and maternal-fetal clinics, where doctor pay is mostly fixed in the short run. Patient volumes at clinics owned a year ago shrank for three straight quarters, which hurt profit margins. In the third quarter, overall patient volume grew 0.3% from a year ago, and Chief Executive Officer Mark S. Ordan said volume performed ahead of internal expectations.
- Overall patient volume at existing clinics: up 0.3%, after falling 2.1% in the second quarter
- Office-based patient services: up 2.9%, reversing three straight quarters of declines
- NICU patient days: down 0.1%, compared with a 3.2% drop in the second quarter
- Hospital-based patient services: down 0.3%, after shrinking 2.8% last quarter
The rebound matters because it happened against a tough comparison from a year ago, when NICU days grew 2.2%. Office visits led the recovery, while hospital baby-care days nearly stabilized. One quarter eases the volume worry but does not settle it, because nine-month NICU days remain down 1.1%.
What to watch: fourth-quarter NICU patient days against last year's 2.0% decline. A positive reading against that easier comparison would show that hospital birth volumes have truly stabilized.
Outlook Raised as Commercial Mix and Hospital Fees Hold Up
Bears worried that expiring health-insurance subsidies would push more patients onto lower-paying government Medicaid plans, and that financially strained hospitals would resist paying administrative fees. Instead, the share of services paid by commercial and other non-government insurers rose 0.7 percentage points from a year ago, following a 1.35-point gain in the second quarter. The physician group also recorded "an increase in administrative fees from our hospital partners" and higher-acuity care in neonatology.
Those steady commercial payments and recent practice acquisitions helped third-quarter Adjusted EBITDA — profit before interest, taxes, depreciation and restructuring — reach $85.5 million. By our math, that beat the $77.7 million middle of the range implied by the prior full-year plan. Management lifted the bottom of its full-year Adjusted EBITDA outlook by $10 million, to $290–300 million, while Ordan said the group is "considering high-value opportunities in adjacent businesses, as they arise".
What to watch: the commercial insurer share and any disclosed numbers on obstetrics hospitalist or tele-hybrid clinic expansion in the fourth quarter. Another commercial mix gain would show that insurance changes are still not hurting reimbursement.
🐻 Bear Case
Pricing Growth Almost Vanished as Collection Gains Lapped
"We are pleased with our results this quarter, driven by both volume and pricing performing ahead of our expectations," Ordan said. Yet reimbursement and pricing growth at clinics owned a year ago slowed to 0.3% from 4.0% in the second quarter and 7.6% a year earlier. The medical group said higher acuity and commercial mix were "partially offset by the benefit from strong improvement in cash collections in the prior year".
For four quarters, faster cash collection from a new billing setup drove most of Pediatrix's pricing gains. Now that collection speed has leveled off against last year's improved baseline, underlying revenue growth at existing clinics slowed to 0.6%. That was not enough to cover rising doctor pay: practice salaries and benefits rose to 68.1% of revenue, up 0.7 percentage points from a year ago, and general and administrative overhead rose 0.2 points to 12.5%.
Because revenue at existing clinics grew slower than clinic payroll, operating margin fell 0.8 percentage points to 13.0%, and Adjusted EBITDA slipped 2.1% from a year ago due to "higher expenses as compared to revenue growth at our existing units". What to watch: fourth-quarter underlying pricing growth and practice salaries as a share of revenue. If pricing stays below 1%, existing clinic margins will keep shrinking.
Buybacks Drive Per-Share Profit Growth While Underlying Profit Stalls
Bulls point to steady share buybacks that shrink the share count and boost earnings per share, while sceptics note that repurchases are partly offset by rising employee stock grants. In the third quarter, Pediatrix spent $83.0 million on share repurchases, nearly doubling its second-quarter spend of $42.7 million and lowering its diluted share count by 6.9% from a year ago to 79.7 million.
That lower share count did all the work for per-share profit. Profit per share excluding one-offs rose 7.5% to $0.72, even though total profit excluding one-offs dipped 0.4% to $57.2 million and GAAP net income fell 16.1% by our math when excluding last year's divestiture gain. Meanwhile, after-tax stock-based compensation excluded from that profit figure jumped 44.6% from a year ago to $3.7 million.
What to watch: fourth-quarter share repurchases and stock-compensation expense in the annual filing. If underlying profit stays flat, per-share growth will depend entirely on further cash outflows for buybacks.
Billing Transition Costs Keep Rising Two Years After Completion
Pediatrix excludes "transformational and restructuring related expenses" from its headline Adjusted EBITDA and Adjusted EPS figures. Management completed its move to a hybrid revenue-cycle billing system in late 2024, yet it still attributes these quarterly charges "primarily related to position eliminations and revenue cycle management transition activities".
In the third quarter, those restructuring charges totaled $6.1 million, using up nearly all of the $7.0 million that the prior full-year plan left for the entire second half by our math. As a result, the company raised its full-year restructuring cost forecast for a third consecutive quarter — from $9.2 million initially, to $13.3 million, then $20.4 million, and now $22.5 million — matching the $22.3 million spent in 2025.
What to watch: the initial 2027 restructuring expense forecast in next quarter's release. Another double-digit million forecast would show that these excluded billing and severance costs are a permanent operating expense.
Risks this quarter didn't answer
Three standing balance-sheet and regulatory concerns received no new data in the third-quarter earnings release.
- February 2027 credit facility maturity: the $178 million Term A loan and $450 million credit line mature in less than four months; the quarterly filing's debt footnote will show if refinancing is complete.
- Federal reimbursement rules: the impact of May 2026 surprise-billing arbitration changes and proposed 2027 Medicare rate cuts awaits management commentary on 2027 pricing.
- Joint-venture acquisition terms: Ordan again mentioned adjacent business opportunities, but no deal size, partner structure or debt limit was disclosed.
👓 Other Themes
New Healthcare Law Added to Formal Policy Risks
In its forward-looking risk disclosures, Pediatrix explicitly added "the One Big Beautiful Bill Act" alongside the Affordable Care Act, state Medicaid budget constraints, and economic slowdowns as policy factors that could alter patient insurance coverage. Because government programs pay substantially less than commercial insurers for neonatal and maternal care, any future federal tightening of Medicaid eligibility or funding under the law remains an external macro watch item.
💲 Other KPIs
Free cash flow — operating cash flow of $117.7 million minus $4.4 million of capital spending, by our math — fell 14.7% from $132.8 million a year ago. After typical first-quarter bonus payouts caused an outflow, cash generation was strong in both the second and third quarters, representing 22.6% of third-quarter revenue.
Total debt of $577.7 million minus $425.8 million of cash and short-term investments left $151.9 million of net debt by our math, up $54.3 million since December. The physician group paid down $19.6 million of Term A loan borrowings over the first nine months, while cash fell due to $147.2 million of share buybacks.
Uncollected patient and hospital bills rose 0.3% from $231.1 million a year ago and 0.9% from $229.7 million at year-end, tracking the 1.7% increase in quarterly revenue. That stability confirms that billing collection speed has leveled off after last year's sharp improvement.
🔮 Guidance
Raised. Management lifted the bottom of the range by $10 million after holding it for two quarters, putting the $295 million middle of the range up 7.0% from 2025. By our math, that leaves $74.9 million for the fourth quarter, up 13.8% against an easy year-ago comparison of $65.8 million.
Raised. The middle of the GAAP net income range moved up $2.3 million to $157.2 million, down 5.0% from 2025 (which included a divestiture gain), after two straight cuts: -$3.0M, -$4.6M, +$2.3M. By our math, the plan leaves $40.7 million for the fourth quarter, up 21.0% from a year ago.
Raised. Expected restructuring charges rose $2.1 million, about 1.0% above 2025's total. It is the third increase in three quarters (+$4.1M, +$7.1M, +$2.1M), and by our math leaves $3.0 million of charges for the fourth quarter, down from $6.1 million in the third quarter.
Cut. The full-year interest estimate dropped by $0.3 million following a $0.4 million reduction last quarter, putting full-year interest down 8.8% from 2025 on lower Term A loan balances. By our math, that leaves $8.2 million for the fourth quarter, compared with $8.1 million in the third quarter.
Raised. The middle of the tax range rose $0.9 million to $58.2 million alongside higher expected pre-tax profit. By our math, that implies $16.7 million of tax expense in the fourth quarter, down from $18.0 million in the third quarter.
Unchanged. The full-year estimate stays at $24.4 million, up 11.8% from 2025 due to recent clinic acquisitions and equipment spending. By our math, that leaves $6.3 million for the fourth quarter, matching the third quarter's $6.2 million.
❓ Key Questions
How and when will the February 2027 credit facility be refinanced?
The $178 million Term A loan and $450 million credit line mature on February 11, 2027. With $425.8 million in cash and short-term investments, investors need to know how much debt Pediatrix will repay in cash versus refinance at current interest rates.
Can existing clinic pricing beat 1% now that collection gains have lapped?
Reimbursement growth at clinics owned a year ago fell from 4.0% to 0.3% as last year's billing improvements entered the comparison base. Without faster collection gains, can commercial mix and hospital fees cover rising doctor salaries in 2027?
Why did billing transition restructuring costs rise for a third time?
Management raised its 2026 restructuring forecast from $9.2 million at the start of the year to $22.5 million, still citing the revenue-cycle billing transition completed in 2024. When will these excluded expenses actually end?
What are the financial guardrails for adjacent business acquisitions?
Chief Executive Officer Mark S. Ordan again highlighted opportunities in adjacent businesses while spending $83 million on third-quarter buybacks. Investors have not seen the revenue size or debt limits for these potential deals.